Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
News-Medical.Net on MSN
CRISPR-Cas3: A safer gene-editing tool shows promise for transthyretin amyloidosis treatment
Genetic disorders occur due to alterations in the primary genetic material, deoxyribonucleic acid (DNA), of an organism.
Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...
CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...
Researchers used fruit flies to uncover genes that regulate both dopamine levels and sleep. By screening pigmentation-related ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
Therapeutic Potential of CRISPR–Cas3 Genome-Editing System for Transthyretin Amyloidosis. Credit: Institute of Medical ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback